<DOC>
	<DOCNO>NCT01640028</DOCNO>
	<brief_summary>The purpose study analyze relationship sebum excretion rate follow factor : - Hormone level ( testosterone , dehydroepiandrosterone sulfate ) - Expression 5-α-reductase type 1 ( protein sebaceous gland transforms hormone ( testosterone ) another one strongly stimulate sebum production ) - Diet - Sun ultraviolet light exposure . - Facial wash routine - Sleep pattern ( time start sleep total sleep time ) This study analyze relationship sebum excretion rate various factor may influence approximately 40 subject . It conduct one center locate Montreal . All device know already use past .</brief_summary>
	<brief_title>Exploratory Study Intra Inter-subject Variability Sebum Excretion Rate</brief_title>
	<detailed_description>A total 40 subject sebum excretion rate least 4 include . Subjects see Day 0 Day 7 . Casual sebum measurement perform least 2 hour wash face morning Sebumeter® follow 30-second application Sebumeter® Measurement Cartridge forehead . Sebum excretion rate measure Sebutape® apply right leave forehead visit . Each Sebutape® scan area cover sebum , see gray-black dot scan Sebutape® , measure image analysis software . Circulating level free testosterone DHEAS measure visit . A skin biopsy behind ear perform Day 0 Day 7 measure gene expression 5-α-reductase type 1 . On Day 0 Day 7 , subject require take 24-hour recall questionnaire . On Day 0 Day 7 , subject question time sleep induction , total sleep time night precede visit , facial wash routine number hour direct indirect UV exposure past 24 hour . On Day 0 Day 7 , subject 's forehead skin temperature measure .</detailed_description>
	<criteria>1 . Subject sebum excretion rate least 4 Day 0 side forehead measure Sebutape . 2 . Subject 18 year age old time consent generally good health . 3 . Female subject willing use effective contraceptive method least 30 day Day 0 end study . Effective contraceptive method : 1 . Barrier method condom , sponge diaphragm combine spermicide foam , gel cream ; 2 . Hormonal contraception ( oral , intramuscular , implant transdermal ) include DepoProvera , Evra Nuvaring ; 3 . Intrauterine device ( IUD ) ; 4 . Sterilization tubal ligation , oophorectomy , hysterectomy vasectomized partner ; 5 . Postmenopausal state least 1 year female subject female partner male subject ; 6 . Samesex partner ; 7 . Abstinence . 4 . Subject negative urine pregnancy test Day 0 visit female subject childbearing potential . 5 . Subject capable give informed consent consent must obtain prior study related procedure . 1 . Subject currently pregnant lactating . 2 . Subject skin condition forehead could interfere sebum excretion measurement except mild acne vulgaris . 3 . Subject receive investigational drug within 28 day 5 halflives , whichever longer , prior Day 0 plan study period . 4 . Subject use topical medication face within 14 day Day 0 plan study . 5 . Subject applied cosmetic emollient forehead morning Day 0 visit plan morning Day 7 visit . 6 . At investigator 's discretion subject current history alcohol drug abuse would interfere ability subject comply study protocol . 7 . Subject use isotretinoin 52 week precede Day 0 plan study . 8 . Subject swum chlorinate water within 24 hour Day 0 visit plan within 24 hour Day 7 visit . 9 . Known hypersensitivity/allergy lidocaine 10 . The subject history keloid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>